Overexpression of cannabinoid receptor CB2 may be a prognostic biomarker for NSCLC adenocarcinomas.
Andrea S. Blevins Primeau, PhD, MBA
Andrea S. Blevins Primeau, PhD, MBA, is a freelance medical writer and editor based in central Pennsylvania. She enjoys writing about a variety of topics including oncology, cardiovascular disease, and autoimmune disorders. Previously, she conducted research investigating the role of pharmacogenetics on the efficacy of oncologic therapies.